GENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations

Stock News05-27

GENSCRIPT BIO (01548) saw its shares rise more than 5%. At the time of writing, the stock was up 5.35% to HKD 13.98, with a turnover of HKD 50.64 million.

The increase follows a recent announcement from GENSCRIPT BIO. Its associated company, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission and issued a press release on May 21, 2026 (prior to the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Among the presentations, a rapid oral session will highlight preliminary Phase 1 clinical data for LB2102. This is an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel) will be presented.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170559238?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170559238","market":"hk","top_or_hot":-1,"title":"GENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) saw its shares rise more than 5%. At the time of writing, the stock was up 5.35% to HKD 13.98, with a turnover of HKD 50.64 million.</p>\n<p>The increase follows a recent announcement from GENSCRIPT BIO. Its associated company, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission and issued a press release on May 21, 2026 (prior to the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p>\n<p>Among the presentations, a rapid oral session will highlight preliminary Phase 1 clinical data for LB2102. This is an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel) will be presented.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO Surges Over 5% Following Partner Legend Biotech's ASCO 2026 Research Presentations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) saw its shares rise more than 5%. At the time of writing, the stock was up 5.35% to HKD 13.98, with a turnover of HKD 50.64 million.</p>\n<p>The increase follows a recent announcement from GENSCRIPT BIO. Its associated company, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission and issued a press release on May 21, 2026 (prior to the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.</p>\n<p>Among the presentations, a rapid oral session will highlight preliminary Phase 1 clinical data for LB2102. This is an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel) will be presented.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1170559238","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170559238","pubTimestamp":1779847357,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) saw its shares rise more than 5%. At the time of writing, the stock was up 5.35% to HKD 13.98, with a turnover of HKD 50.64 million. The increase follows a recent announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK1141":"生命科学工具和服务","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4139":"生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","01548":"金斯瑞生物科技","LEGN":"传奇生物","BK1583":"高瓴概念","BK1576":"医药外包概念"},"translate_title":"合作伙伴Legend Biotech在ASCO 2026研究演示后，金斯瑞生物股价飙升超过5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"LEGN":1,"VXUS":1},"content_text":"GENSCRIPT BIO (01548) saw its shares rise more than 5%. At the time of writing, the stock was up 5.35% to HKD 13.98, with a turnover of HKD 50.64 million.\nThe increase follows a recent announcement from GENSCRIPT BIO. Its associated company, Legend Biotech Corporation, submitted a Form 6-K to the U.S. Securities and Exchange Commission and issued a press release on May 21, 2026 (prior to the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.\nAmong the presentations, a rapid oral session will highlight preliminary Phase 1 clinical data for LB2102. This is an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel) will be presented.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170559238","isCrawlerRequest":true}